title: Controversies in the role of radiotherapy in the treatment of pediatric Hodgkin lymphoma.
abstract: Hodgkin lymphoma in children is a highly curable malignancy with current approaches utilizing combined modality therapy and a risk-adapted approach. The combination of anthracyclines, bleomycin, and radiotherapy, as well as other alkylating agents, are significant risk factors for secondary malignancies and cardiopulmonary toxicity. Therefore, current strategies aim to optimize cure rates while minimizing late effects. The role of radiotherapy has been examined in recent pediatric trials, with varying results. However, they provide evidence, as a whole, for the omission of radiotherapy for a subgroup of patients, without compromising outcomes.
authors: Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital of Michigan, Detroit, MI, 48201, USA, mhenry@med.wayne.edu.
authors: Meret
authors: M
authors: Henry
authors: Süreyya
authors: S
authors: Savaşan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D000075202:Contraindications; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D011878:Radiotherapy; D018570:Risk Assessment; D012307:Risk Factors
references: Radiat Res. 2010 Dec;174(6):741-52
references: 21128798
references: Lancet. 2012 May 12;379(9828):1791-9
references: 22480758
references: JAMA. 2012 Jun 27;307(24):2609-16
references: 22735430
references: Pediatr Blood Cancer. 2012 Dec 15;59(7):1284-9
references: 22847767
references: Blood. 2012 Oct 18;120(16):3280-7
references: 22948049
references: J Clin Oncol. 2010 Aug 10;28(23):3680-6
references: 20625128
references: Blood. 2011 Mar 3;117(9):2596-603
references: 21079154
references: Blood. 2009 Sep 3;114(10):2051-9
references: 19584400
references: J Clin Oncol. 1999 Dec;17(12):3736-44
references: 10577845
references: Klin Padiatr. 2003 May-Jun;215(3):139-45
references: 12838937
references: Pediatr Blood Cancer. 2010 Dec 1;55(6):1145-52
references: 20734400
references: J Clin Res Pediatr Endocrinol. 2011;3(2):89-94
references: 21750638
references: Haematologica. 2011 Feb;96(2):269-76
references: 21071500
references: N Engl J Med. 2010 Mar 11;362(10):875-85
references: 20220182
references: Blood. 2011 Feb 10;117(6):1806-16
references: 21037086
references: Ann Oncol. 2002;13 Suppl 1:107-11
references: 12078889
references: Ann Oncol. 2011 Dec;22(12):2569-2574
references: 21393381
references: Br J Haematol. 2012 Sep;158(5):615-25
references: 22775513
references: J Clin Oncol. 1997 Aug;15(8):2769-79
references: 9256118
references: J Pediatr Hematol Oncol. 2006 Jun;28(6):362-8
references: 16794504
references: J Clin Oncol. 2012 Sep 10;30(26):3174-80
references: 22649136
references: J Clin Oncol. 2002 Sep 15;20(18):3765-71
references: 12228196
references: J Clin Oncol. 2010 Mar 1;28(7):1232-9
references: 20124178
references: Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65
references: 22911615